[{"address1": "100 Overlook Center", "address2": "Suite 102", "city": "Princeton", "state": "NJ", "zip": "08540", "country": "United States", "phone": "609 375 2227", "website": "https://www.sonnetbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "As of December 2, 2025, Sonnet BioTherapeutics Holdings, Inc. was acquired by Hyperliquid Strategies Inc, in a reverse merger transaction. Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.", "fullTimeEmployees": 13, "companyOfficers": [], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.1, "open": 3.16, "dayLow": 1.26, "dayHigh": 3.23, "regularMarketPreviousClose": 3.1, "regularMarketOpen": 3.16, "regularMarketDayLow": 1.26, "regularMarketDayHigh": 3.23, "payoutRatio": 0.0, "beta": 1.471, "forwardPE": -0.0842246, "volume": 10428964, "regularMarketVolume": 10428964, "averageVolume": 892227, "averageVolume10days": 1615087, "averageDailyVolume10Day": 1615087, "bid": 1.25, "ask": 1.31, "bidSize": 100, "askSize": 200, "marketCap": 8602465, "fiftyTwoWeekLow": 1.08, "fiftyTwoWeekHigh": 19.3, "allTimeHigh": 39916.797, "allTimeLow": 1.08, "priceToSalesTrailing12Months": 8.602465, "fiftyDayAverage": 4.5801, "twoHundredDayAverage": 3.042017, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 8258023, "profitMargins": 0.0, "floatShares": 6743545, "sharesOutstanding": 6827352, "sharesShort": 2151547, "sharesShortPriorMonth": 2184854, "sharesShortPreviousMonthDate": 1760486400, "dateShortInterest": 1763078400, "sharesPercentSharesOut": 0.3151, "heldPercentInsiders": 0.04247, "heldPercentInstitutions": 0.09946, "shortRatio": 3.27, "shortPercentOfFloat": 0.3156, "impliedSharesOutstanding": 6827353, "bookValue": -0.914, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -13556225, "trailingEps": -6.82, "forwardEps": -14.96, "lastSplitFactor": "1:8", "lastSplitDate": 1727654400, "enterpriseToRevenue": 8.258, "enterpriseToEbitda": -0.588, "52WeekChange": -0.26744187, "SandP52WeekChange": 0.19362879, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SONN", "underlyingSymbol": "SONN", "shortName": "Sonnet BioTherapeutics Holdings", "longName": "Sonnet BioTherapeutics Holdings, Inc.", "firstTradeDateEpochUtc": 1585834200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e0f4f091-b896-3bb3-bb50-c62febf22cab", "messageBoardId": "finmb_410378138", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.26, "targetHighPrice": 20.0, "targetLowPrice": 20.0, "targetMeanPrice": 20.0, "targetMedianPrice": 20.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 321297, "totalCashPerShare": 0.048, "ebitda": -14047793, "totalDebt": 68837, "quickRatio": 0.18, "currentRatio": 0.259, "totalRevenue": 1000000, "revenuePerShare": 0.369, "returnOnAssets": -2.23803, "grossProfits": -767527, "freeCashflow": -6010179, "operatingCashflow": -10310714, "grossMargins": -0.76752996, "ebitdaMargins": 0.0, "operatingMargins": -14.058669, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2026-01-10"}]